Definiens introduced its latest CAD system as a way to judge the effects of therapy on some cancer patients.
Definiens introduced its latest CAD system as a way to judge the effects of therapy on some cancer patients. Dubbed LymphExpert, the CAD technology helps detect the metastatic spread of cancer by better identifying, analyzing, and measuring volumetric changes in the size of lymph nodes. The CAD software promises to save time and make study results more consistent by automating segmentation and analysis of the nodes.
LymphExpert is brought in after a radiologist has manually detected lymph nodes in a CT image, automatically segmenting and quantifying the nodes according to established guidelines, then reconstructing a volumetric image. Definiens contends that a precise 3D picture of a lymph node's growth or shrinkage over time indicates cancer progression or remission. The Munich-based company, founded in 1986 by Nobel Laureate Gerd Binnig, develops "cognitive emulation" software that automates and quantifies challenging image analysis challenges.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.